On December 16, 2021 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug candidate ATOR-1017, which is developed as a tumor-directed therapy for metastatic cancer (Press release, Alligator Bioscience, DEC 16, 2021, View Source [SID1234597275]). The early readout data corroborates previous data on biomarkers, safety and tolerability, sustaining a safety profile up to and including a dose of 360 mg with no dose limiting toxicities reported.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase I study with ATOR-1017 is a first-in-human, open-label, dose escalation study in patients with advanced solid cancer (NCT04144842). The primary objective of the study is to investigate the safety and tolerability of ATOR-1017, and to determine the recommended dose for subsequent Phase II studies. The results from the current evaluation shows that ATOR-1017 has an encouraging safety profile. Again, there was no dose-limiting toxicity or severe immune-related adverse events. The results support data from earlier read-outs that ATOR-1017 exhibits a favorable pharmacokinetic profile. Additionally, it confirms and extends previous biomarker data demonstrating proof of mechanism of ATOR-1017, including increased proliferation of circulating T-cells and dose-dependent increases in soluble 4-1BB, both biomarkers of T-cell activation. A full data read-out is expected in Q1 2022.
Earlier this year, the Company announced results that validated the therapeutic potential of ATOR-1017 demonstrating a very favorable safety profile combined with clear signs of proof of mechanism, as activation of T cells in the circulation was observed across active dose levels of ATOR-1017 in a poster presentation at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting (link to press release).
"We are extremely pleased with the confirmatory data as it strengthens the case for the safety and tolerability as well as confirming the proof of mechanism of ATOR-1017. We are excited by this outcome and are working hard on completing this study and determining the dose for a subsequent Phase II program," said Søren Bregenholt, CEO of Alligator Bioscience.